Bespak addresses India’s biopharmaceutical drive for high value drug delivery products that differentiate generics, biobetters and biosimilars at CPHI India 2015
The company showcases the innovative Syrina 2.25 auto-injector that brings the flexibility to design a unique form factor and also the full Syrina platform accommodating multiple primary containers and high viscous, high volume injections.
Bespak is attending CPHI India 2015, and is utilising the internationally sponsored event to meet clients and to further highlight how its technology, in the field of combination products, auto-injectors and pen injectors, can best assist the complex requirements of India based biopharmaceutical companies. To date, Bespak has built-up and established strong customer relationships with many of the country’s leading biopharmaceutical companies for a range of products from Metered Dose Inhaler (MDI) valves, injectables, respiratory devices and more.
Steven Kaufman, Bespak’s Global Business Development Lead, commented: “India’s biopharmaceutical sector is on the look-out for highly innovative drug and delivery device solutions that provide a competitive edge for their products. Consequently, we are seeking to use this event to maintain our close relationships with our customers, whilst demonstrating how we can best service their needs with advanced drug delivery device technology that further increases value by helping to differentiate their generic, biobetter and biosimilar drugs.”
He continued: “For example, we will be demonstrating how our latest addition to the Syrina product range, the Syrina 2.25, which utilises cutting edge drug delivery technology, brings the flexibility of being able to design a truly unique form factor to the market.”
Syrina 2.25 utilises the standard 2.25ml pre-filled syringe, based on Bespak’s proprietary VapourSoft™ technology and will also be available in a 1-mlLversion.
The VapourSoft powerpack system helps overcome issues seen in spring-based auto-injectors. Based on proven valve technology, a small novel container of liquefied gas serves as a new power source. The propellant, when released, provides sufficient energy, in the form of a pressurised vapour, to power drug delivery and other functions. The consistent delivery performance across the Syrina product range gives researchers and biopharmaceutical companies the ability to use Syrina with VapourSoft at a very early stage of development. Several variations of the devices are available for clinical trials with a range of industrial designs being considered for the body of the auto-injectors to best suit patient needs. The Syrina auto injector with VapourSoft platform is proven to accommodate multiple primary containers, as well as high viscosity and high volume injections.
Related News
-
.png)
News CPHI Online Trend Report – 2025 Pharma Packaging Prospects
The pharmaceutical packaging market has seen marked shifts in innovations, priorities, and focus over the last few years. With the rise of hit drugs like GLP-1 agonists and biologics requiring specialised packaging considerations, the strain of meeting... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance